Moderna Inc
NASDAQ:MRNA

Watchlist Manager
Moderna Inc Logo
Moderna Inc
NASDAQ:MRNA
Watchlist
Price: 39.52 USD 0.33%
Market Cap: 15.2B USD
Have any thoughts about
Moderna Inc?
Write Note

Moderna Inc
Short-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Moderna Inc
Short-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
Moderna Inc
NASDAQ:MRNA
Short-Term Investments
$5.2B
CAGR 3-Years
16%
CAGR 5-Years
43%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Short-Term Investments
$28m
CAGR 3-Years
-25%
CAGR 5-Years
N/A
CAGR 10-Years
12%
Gilead Sciences Inc
NASDAQ:GILD
Short-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Short-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Short-Term Investments
$1.3B
CAGR 3-Years
23%
CAGR 5-Years
17%
CAGR 10-Years
5%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Short-Term Investments
$7.8B
CAGR 3-Years
49%
CAGR 5-Years
39%
CAGR 10-Years
35%
No Stocks Found

Moderna Inc
Glance View

Market Cap
15.2B USD
Industry
Biotechnology
Economic Moat
None

In the vibrant world of biotechnology, Moderna Inc. stands as a remarkable testament to the fusion of cutting-edge science and swift innovation. Founded in 2010 and based in Cambridge, Massachusetts, Moderna has crafted its niche in messenger RNA (mRNA) technology, pivoting the traditional paradigms of drug development. The company’s unique approach utilizes synthetic mRNA to direct cells in the body to produce proteins that can prevent, treat, or cure diseases. This innovative platform enables rapid testing and development of medicines across a wide array of therapeutic areas, from infectious diseases to oncology, leveraging its flexible technology to address significant unmet medical needs. Moderna’s story gained global prominence in the context of the COVID-19 pandemic, when its vaccine, one of the first to be authorized, became crucial in combatting the virus, highlighting the potential of mRNA technology on a global stage. Financially, Moderna’s business model is driven by a combination of strategic partnerships, robust research and development capabilities, and the commercialization of its mRNA products. The company collaborates extensively with government agencies, global health organizations, and biopharmaceutical enterprises to both advance its pipeline and maximize its market reach. Revenue is primarily generated through the sale of its COVID-19 vaccine, alongside income from grants and collaboration agreements. Moreover, Moderna continually invests in expanding its mRNA platform and portfolio, seeking long-term value creation by targeting diverse therapeutic areas such as rare diseases, autoimmune disorders, and personalized cancer vaccines. By reinvesting in innovation and scaling its manufacturing capabilities, Moderna is not just a quintessential biotech enterprise but a harbinger of a new era in medical science.

MRNA Intrinsic Value
48.53 USD
Undervaluation 19%
Intrinsic Value
Price

See Also

What is Moderna Inc's Short-Term Investments?
Short-Term Investments
5.2B USD

Based on the financial report for Sep 30, 2024, Moderna Inc's Short-Term Investments amounts to 5.2B USD.

What is Moderna Inc's Short-Term Investments growth rate?
Short-Term Investments CAGR 5Y
43%

Over the last year, the Short-Term Investments growth was 13%. The average annual Short-Term Investments growth rates for Moderna Inc have been 16% over the past three years , 43% over the past five years .

Back to Top